These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 10631716)
1. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716 [TBL] [Abstract][Full Text] [Related]
2. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. Blok P; Craanen ME; Dekker W; Offerhaus GJ; Tytgat GN J Pathol; 1998 Sep; 186(1):36-40. PubMed ID: 9875138 [TBL] [Abstract][Full Text] [Related]
3. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665 [TBL] [Abstract][Full Text] [Related]
4. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases. Emanuels AG; Koudstaal J; Burger MP; Hollema H Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975 [TBL] [Abstract][Full Text] [Related]
5. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476 [TBL] [Abstract][Full Text] [Related]
9. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361 [TBL] [Abstract][Full Text] [Related]
10. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Haitel A; Wiener HG; Baethge U; Marberger M; Susani M Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906 [TBL] [Abstract][Full Text] [Related]
11. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719 [TBL] [Abstract][Full Text] [Related]
12. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Liu XP; Tsushimi K; Tsushimi M; Oga A; Kawauchi S; Furuya T; Sasaki K Pathol Int; 2001 Jun; 51(6):440-4. PubMed ID: 11422805 [TBL] [Abstract][Full Text] [Related]
13. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2]. Villaseca M; Araya JC; Roa I; Roa JC Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880 [TBL] [Abstract][Full Text] [Related]
14. Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma. Yao D; Wang Y; Xue L; Wang H; Zhang J; Zhang X Hum Pathol; 2013 May; 44(5):844-51. PubMed ID: 23159155 [TBL] [Abstract][Full Text] [Related]
15. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. Abdel-Fattah G; Yoffe B; Krishnan B; Khaoustov V; Itani K J Gastrointest Surg; 2000; 4(1):109-14. PubMed ID: 10631371 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas. Harlozińska A; Bar J; Montenarh M Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396 [TBL] [Abstract][Full Text] [Related]
17. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050 [TBL] [Abstract][Full Text] [Related]
18. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998 [TBL] [Abstract][Full Text] [Related]
19. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features. Horie S; Maeta H; Endo K; Ueta T; Takashima K; Terada T Pathol Int; 2001 Jan; 51(1):11-5. PubMed ID: 11148457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]